Friday, July 10, 2026

Drug profile · INN

anagliptin

anagliptin (SUINY) is a dipeptidyl peptidase iv inhibitor.

PMDA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — anagliptin
Class
Route
Patents
0
Programs
0
Data quality
0.78

Quick answer

anagliptin (SUINY) is a dipeptidyl peptidase iv inhibitor.

Key facts

INN anagliptin
Brand SUINY
Mechanism Dipeptidyl peptidase IV inhibitor
Target Dipeptidyl peptidase 4

Mechanism of action

Dipeptidyl peptidase IV inhibitor

Primary target: Dipeptidyl peptidase 4

Approval history

Authority Status Date
PMDA approved

Related & competitor drugs

  1. alogliptin benzoate Alimentary tract and metabolism (A10)
  2. linagliptin Alimentary tract and metabolism (A10)
  3. saxagliptin hydrochloride Dipeptidyl peptidase IV inhibitor
  4. sitagliptin phosphate Dipeptidyl peptidase IV inhibitor
  5. begelomab Antineoplastic and immunomodulating agents (L04)
  6. sitagliptin fumarate Alimentary tract and metabolism (A10)

Frequently asked questions

What is anagliptin?

anagliptin (SUINY) is a dipeptidyl peptidase iv inhibitor.

What is the brand name for anagliptin?

SUINY is a marketed brand name for anagliptin. Check FDA Drugs@FDA for the current US label holder and prescribing information.